Exploring new ways to treat treatment-resistant depression using mitochondrial metabolism.
A translational approach for novel mechanisms of epigenetic regulation in treatment responses: toward a precision medicine model
This study is looking at how a substance called L-acetylcarnitine might help people with treatment-resistant depression feel better, and it will explore how this works in the brain and if it affects men and women differently.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11000837 on NIH RePORTER |
What this research studies
This research investigates how a mitochondrial metabolite called L-acetylcarnitine (LAC) can improve treatment responses in patients with treatment-resistant depression (TRD). By examining the effects of LAC on brain chemistry and its interaction with specific receptors, the study aims to uncover new mechanisms that could lead to more effective therapies. The research will also analyze how these effects vary between different patient groups, particularly focusing on sex differences. Patients may be involved in assessments that track their responses to treatment over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with treatment-resistant depression who have not responded to standard antidepressant therapies.
Not a fit: Patients with mild depression or those who have not been diagnosed with treatment-resistant depression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for individuals suffering from treatment-resistant depression.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting mitochondrial metabolism in depression treatment, suggesting potential for success in this study.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Nasca, Carla — New York University School of Medicine
- Study coordinator: Nasca, Carla
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.